Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 (NCT03298061), a na phase 3 study. The primary outcome is Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs).

2. Clinical Question

3. Trial Design

This is a Phase 3, open-label, single-group long-term access program sponsored by GlaxoSmithKline. The registry lists enrollment of 100 and a completed status. The recorded start date is 2015-04-14, and primary completion is listed as 2023-02-16. Allocation is not applicable, and masking is none.

The program was intended for eligible participants from MEA115921 who required prednisolone, or an equivalent, at 5 mg/day for adequate EGPA control. The registry describes subcutaneous mepolizumab at 300 mg every 4 weeks. The brief summary states that eligible participants could begin the program within a 6-month period after completion of MEA115921, or at the corresponding Week 60 point if they had discontinued that study early.

The earlier MEA115921 study is described as placebo-controlled and as involving background standard-of-care therapy. That description supplies context for participant eligibility; it does not make this access program a placebo-controlled study. There is no concurrent control group in the program’s posted results, so comparisons with the earlier study would not be like-for-like.

The primary safety timeframe is listed as up to approximately 89 Months. On-treatment AEs and SAEs are defined as events occurring on or after the first open-label dose and on or before the last dose plus 28 days. The registry record does not report further detail about treatment duration for each participant, adherence, or follow-up completeness.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 100 participants entered the study and received mepolizumab.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety Population consisted of all participants who received at least one dose of open label mepolizumab. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), measured over Up to approximately 89 Months.

The primary outcome is the number of participants with AEs and SAEs. An AE is defined as an untoward medical occurrence temporally associated with use of a medicinal product, whether or not it is considered related to that product. An SAE is an event meeting specified seriousness criteria, including death, life-threatening events, hospitalization or prolonged hospitalization, disability or incapacity, congenital anomaly or birth defect, and other important events based on medical or scientific judgment. The description also includes liver injury with impaired liver function.

The registry states that systemic reactions, including allergic or hypersensitivity and non-allergic reactions, and local injection-site reactions were recorded throughout treatment and follow-up. The endpoint is useful for describing how many participants experienced events classified as AEs or SAEs in this safety population. Because it is a participant count, it does not indicate the total number of separate events, their duration, severity distribution, or causal relationship to treatment.

For the posted primary outcome, the mepolizumab group has 100 at risk, 97 participants with AEs, and 38 with SAEs. Those counts are descriptive. In the absence of a concurrent control group and comparative analyses, they do not estimate how event occurrence differed from another treatment or from no program treatment.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a count of participants with AEs and SAEs. This kind of outcome records whether each participant experienced an event meeting the relevant definition during the specified period. It is different from an event count: repeated events in the same participant do not necessarily increase the number of participants counted for that participant-level outcome.

What does a participant count describe?

For the primary result, 100 participants are listed as at risk. The reported counts are 97 with AEs and 38 with SAEs. These figures describe the safety population as defined in the record: participants who received at least one dose of open-label mepolizumab. The count does not describe the number of events, the time to an event, or how often events recurred.

General: binary outcomes are commonly analyzed by classifying each participant as having or not having the event of interest. A proportion can then be used to summarize the frequency within a group. Interpretation depends on the population included, the event definition, the observation window, and how missing outcome information is handled. No additional adjusted or comparative analysis is listed for this outcome in the registry record.

Why does the design matter?

This program is open-label and single group, with no concurrent comparator. Consequently, the results are descriptive rather than a treatment contrast. In a randomized comparison, a difference between groups can be estimated under the trial’s design and analysis assumptions. Here, there is no program control group from which to estimate such a difference. The placebo-controlled study mentioned in the background is MEA115921, the study from which participants came; it is not the control arm for this access program.

General: randomization can help balance both measured and unmeasured factors between groups, while a concurrent control also provides a reference observed over a similar period. Without that reference, changes or events may reflect the disease, background therapy, participant characteristics, or other factors as well as exposure to the study treatment. This is why the observed safety counts should not be interpreted as a causal estimate of treatment effect.

What do the event definitions add?

The AE definition includes any untoward medical occurrence temporally associated with use of a medicinal product, whether or not considered related to it. The SAE definition applies seriousness criteria, including death, life-threatening events, hospitalization or prolonged hospitalization, disability or incapacity, congenital anomaly or birth defect, and other important medical events based on medical or scientific judgment. The description also identifies liver injury with impaired liver function. These categories are classifications, not proof that the study treatment caused an event.

The record defines on-treatment events as occurring on or after the first open-label dose and on or before the last dose plus 28 days. It states that systemic reactions and local injection-site reactions were recorded through treatment and follow-up. The primary outcome timeframe is up to approximately 89 Months. The record does not report person-time by participant or an analysis accounting for different exposure durations. Thus, the counts should not be read as event rates adjusted for time exposed.

How should the listed percentages be read?

The serious-event terms are accompanied by percentages: asthma, 6.0%; eosinophilic granulomatosis with polyangiitis, 3.0%; pneumonia, 3.0%; atrial fibrillation, 2.0%; myocardial infarction, 2.0%; and bronchitis, 2.0%. They are registry-listed term percentages, not comparative effects. The record does not report whether terms are mutually exclusive, whether a participant could appear under multiple terms, or whether each listed event was considered treatment-related.

General: over-dispersion is relevant when count data vary more than a chosen statistical model expects; a model that ignores this extra variability can understate uncertainty. It is not a reported analysis feature for this primary endpoint, which counts participants with an event rather than modeling a series of event counts. The registry record does not report a model for recurrent events, time-to-event analysis, confidence intervals, or hypothesis tests.

The record describes a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. Such planning illustrations are not observed trial outcomes or observed power. No numerical sample-size illustration values are reported in the registry record considered for this interpretation, and no trial-specific sample-size justification or statistical plan is reported.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary outcome measure and no analyses. It does not report a multiplicity adjustment, a hierarchy of hypotheses, or a strategy for controlling false-positive findings across multiple tests. Since no inferential analyses are listed, the record does not establish how multiplicity would have been addressed for any additional analyses.

The safety population is defined as all participants who received at least one dose of open-label mepolizumab. The primary measure lists 100 at risk. The registry record does not report how missing safety information was handled, whether all participants had complete follow-up for the full observation period, or whether any participants discontinued treatment or observation.

General: an analysis population defines which participants contribute to an estimate, while missing-data methods describe how unavailable measurements or outcomes are treated. These choices can affect interpretation, especially when follow-up differs across participants or missingness is related to health status. A participant count for an event is not enough to determine whether missing observations could have changed the result.

The endpoint’s on-treatment window is specified as starting on or after the first open-label dose and ending on or before the last dose plus 28 days. The registry also gives an outcome timeframe of up to approximately 89 Months. It does not report how observation time varied among participants or how events outside the on-treatment window were analyzed. Those details are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 3% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: asthma (6.0%), eosinophilic granulomatosis with polyangiitis (3.0%), pneumonia (3.0%), atrial fibrillation (2.0%), myocardial infarction (2.0%).

The safety result lists 100 participants at risk, 38 participants with SAEs, and 97 participants with AEs in the mepolizumab group. These are participant counts under the registry’s safety-population definition, not totals of every event episode. The record separately lists one death.

SAEs are classified by seriousness criteria, not by whether an event was caused by treatment. The listed serious-event terms and percentages include asthma at 6.0%; eosinophilic granulomatosis with polyangiitis and pneumonia at 3.0% each; and atrial fibrillation, myocardial infarction, and bronchitis at 2.0% each. These are descriptions of recorded terms, not estimates of excess risk compared with a control group.

The program has no concurrent control arm, and the record does not report treatment attribution for these events or details of the death. A count alone also does not convey severity beyond the SAE classification, event duration, recurrence, or timing. The stated on-treatment period runs from the first dose through the last dose plus 28 days; the record does not clarify the timing of each listed event in this summary.

12. What the Result Does, and Does Not, Mean

The results describe adverse events recorded among participants receiving open-label mepolizumab through a long-term access program. The primary outcome reports 97 participants with AEs and 38 with SAEs among 100 at risk. The record also lists one death and provides percentages for selected serious adverse event terms. These data are relevant as a descriptive account of the safety experience captured by the registry.

They do not demonstrate that mepolizumab caused any particular event, nor do they establish that the treatment increased or reduced event occurrence. The AE definition includes events whether or not considered related to a medicinal product, while the SAE definition is based on seriousness criteria. The registry does not provide an attribution analysis or a concurrent comparator for these results.

The program enrolled eligible participants who had previously participated in MEA115921 and required prednisolone, or an equivalent, at 5 mg/day for adequate EGPA control. That eligibility makes the findings specific to this access-program population. The results should not be assumed to describe people outside that population or a different care setting.

The record’s reference to the placebo-controlled MEA115921 study does not make the access-program results a randomized comparison. Participants in this program received open-label mepolizumab, and the registry does not report a contemporaneous placebo group. Any comparison with another study would need to account for differences in participants, follow-up, treatment context, and outcome ascertainment; those comparative data and analyses are not reported in the registry record.

General: statistical evidence is strongest for the question a study design and analysis directly address. A single-group safety count can describe recorded events, but it cannot by itself estimate a counterfactual outcome—what would have happened to the same participants under another treatment. The counts therefore support a descriptive interpretation only, with causal and comparative conclusions beyond what the registry reports.

13. Why This Trial Matters Statistically

This program illustrates why study purpose and design must be considered before interpreting an outcome. The registry describes a long-term access program for eligible participants from MEA115921, rather than a new randomized efficacy comparison. Its primary result is a safety count, and the study has no concurrent control arm.

That distinction matters statistically because a participant count can be informative without answering whether an outcome was more common because of treatment. The registry reports 97 participants with AEs and 38 with SAEs among 100 at risk, but the single-group design does not provide a direct reference for comparing those counts. The program therefore offers descriptive safety information, not a comparative estimate.

The record also illustrates the importance of outcome definitions and populations. The safety population includes participants who received at least one dose of open-label mepolizumab. AEs include occurrences whether or not considered related to treatment, while SAEs are defined by seriousness criteria. On-treatment events are bounded by the first dose and the last dose plus 28 days. A reader needs those definitions to understand what the counts represent.

Finally, a long observation timeframe and a list of serious event terms can add context, but they do not replace details about exposure time, missing data, event attribution, or comparative analyses. The registry does not report those further analyses. Statistically, the appropriate reading is careful and limited: the record documents events in this selected access-program population, while leaving treatment comparisons and causal interpretation unresolved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the single-group, open-label design. There is no concurrent comparator, so the posted counts cannot establish whether AE or SAE occurrence differed from what would have been observed under another treatment or no program treatment. The placebo-controlled design described in the registry belongs to MEA115921, not to this access program.

The program’s population is selected: participants had taken part in MEA115921 and required prednisolone, or an equivalent, at 5 mg/day for adequate EGPA control. This limits how broadly the observed safety counts can be generalized. The registry does not report further participant characteristics that would allow more detailed assessment of representativeness.

The primary outcome is a count of participants with AEs and SAEs. It does not provide the total number of event episodes, recurrence, time to event, or duration. The registry’s on-treatment event definition and maximum timeframe give useful boundaries, but participant-level exposure and follow-up duration are not reported in the registry record.

The record lists one death but does not report its cause, timing, or treatment relationship in this summary. It also does not report treatment attribution for the SAE terms, whether terms overlap, or how missing safety information was handled. No confidence intervals, hypothesis tests, adjusted estimates, or comparative analyses are listed. These omissions limit assessment of precision and prevent causal or comparative conclusions from the posted counts.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 — NCT03298061.
• Registry record last updated 2024-03-12; status last verified 2024-02.
• Results first posted 2024-03-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03298061 is a completed Phase 3, open-label, single-group long-term access program sponsored by GlaxoSmithKline. It was intended for eligible participants from MEA115921 who required prednisolone, or an equivalent, at 5 mg/day for adequate EGPA control. The registry describes mepolizumab at 300 mg subcutaneously every 4 weeks.

The primary outcome counts participants with AEs and SAEs over a timeframe of up to approximately 89 Months. The safety population consists of participants who received at least one dose of open-label mepolizumab. The registry reports 100 at risk, 97 with AEs, and 38 with SAEs; it also lists one death and selected serious adverse event terms with percentages.

Because the program has no concurrent control group and no analyses are listed, these results are descriptive safety observations. The registry record does not report comparative or causal estimates, or further statistical analyses of the primary outcome.